EU/3/06/423

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2015 on request of the sponsor.

On 18 December 2006, orphan designation (EU/3/06/423) was granted by the European Commission to Orfagen, France, for tazarotene for the treatment of congenital ichthyoses.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Tazarotene
Disease / condition
Treatment of congenital ichthyoses
Date of first decision
18/12/2006
Outcome
Withdrawn
EU designation number
EU/3/06/423

Sponsor's contact details

Orfagen
CRDPF Langlade
3 Avenue Hubert Curien - BP 13562
31035 Toulouse Cedex 1
France
Tel. +33 5 34 50 64 58
Fax +33 5 34 50 34 57
E-mail info@orfagen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating